Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

被引：21

作者：

Passaro, Antonio ^{[1
]}

Lazzari, Chiara ^{[1
,2
]}

Karachaliou, Niki ^{[3
]}

Spitaleri, Gianluca ^{[1
]}

Pochesci, Alessia ^{[1
]}

Catania, Chiara ^{[1
]}

Rosell, Rafael ^{[4
]}

de Marinis, Filippo ^{[1
]}

机构：

[1] European Inst Oncol, Div Thorac Oncol, Via G Ripamonti 435, I-20141 Milan, Italy

[2] Ist Sci San Raffaele, Div Expt Med, Dept Med Oncol, Milan, Italy

[3] Quiron Dexeus Univ Hosp, Oncol Inst Dr Rosell, Barcelona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

来源：

ONCOTARGETS AND THERAPY | 2016年 / 9卷

关键词：

ALK; NSCLC; crizotinib; ceritinib; alectinib; brigatinib; lorlatinib; brain metastases; MULTICENTER PHASE-II; EML4-ALK FUSION TRANSCRIPTS; MULTIPLEXED GENE-EXPRESSION; CIRCULATING TUMOR-CELLS; INHIBITOR ALECTINIB; ANAPLASTIC LYMPHOMA; ANTITUMOR-ACTIVITY; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE; BRAIN METASTASES;

D O I：

10.2147/OTT.S98347

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients inevitably develop acquired resistance, showing disease progression in the brain or in other parenchymal sites. Second-or third-generation ALK TKIs have shown to be active in crizotinib-pretreated or crizotinib-naive ALK-positive patients, even in those with brain metastases. In this review, the current knowledge regarding ALK-positive NSCLC, focusing on the biology of the disease and the available therapeutic options are discussed.

引用

页码：6361 / 6376

页数：16

共 109 条

[11] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].

Choi, Young Lim ;

Soda, Manabu ;

Yamashita, Yoshihiro ;

Ueno, Toshihide ;

Takashima, Junpei ;

Nakajima, Takahiro ;

Yatabe, Yasushi ;

Takeuchi, Kengo ;

Hamada, Toru ;

Haruta, Hidenori ;

Ishikawa, Yuichi ;

Kimura, Hideki ;

Mitsudomi, Tetsuya ;

Tanio, Yoshiro ;

Mano, Hiroyuki .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739

[12] Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma [J].

Christensen, James G. ;

Zou, Helen Y. ;

Arango, Maria E. ;

Li, Qiuhua ;

Lee, Joseph H. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Alton, Gordon R. ;

Mroczkowski, Barbara ;

Los, Gerrit .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) :3314-3322

[13] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases [J].

Costa, Daniel B. ;

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Ahn, Myung-Ju ;

Zhou, Caicun ;

Shreeve, S. Martin ;

Selaru, Paulina ;

Polli, Anna ;

Schnell, Patrick ;

Wilner, Keith D. ;

Wiltshire, Robin ;

Camidge, D. Ross ;

Crino, Lucio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1881-1888

[14] CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib [J].

Costa, Daniel B. ;

Kobayashi, Susumu ;

Pandya, Shuchi S. ;

Yeo, Wee-Lee ;

Shen, Zhongzhou ;

Tan, Weiwei ;

Wilner, Keith D. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :E443-E445

[15] Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [J].

Crino, Lucio ;

Ahn, Myung-Ju ;

De Marinis, Filippo ;

Groen, Harry J. M. ;

Wakelee, Heather ;

Hida, Toyoaki ;

Mok, Tony ;

Spigel, David ;

Felip, Enriqueta ;

Nishio, Makoto ;

Scagliotti, Giorgio ;

Branle, Fabrice ;

Emeremni, Chetachi ;

Quadrigli, Massimiliano ;

Zhang, Jie ;

Shaw, Alice T. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2866-+

[16] Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J].

Crystal, Adam S. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Friboulet, Luc ;

Niederst, Matthew J. ;

Lockerman, Elizabeth L. ;

Frias, Rosa L. ;

Gainor, Justin F. ;

Amzallag, Arnaud ;

Greninger, Patricia ;

Lee, Dana ;

Kalsy, Anuj ;

Gomez-Caraballo, Maria ;

Elamine, Leila ;

Howe, Emily ;

Hur, Wooyoung ;

Lifshits, Eugene ;

Robinson, Hayley E. ;

Katayama, Ryohei ;

Faber, Anthony C. ;

Awad, Mark M. ;

Ramaswamy, Sridhar ;

Mino-Kenudson, Mari ;

Iafrate, A. John ;

Benes, Cyril H. ;

Engelman, Jeffrey A. .

SCIENCE, 2014, 346 (6216) :1480-1486

[17] Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) [J].

Cui, J. Jean ;

Tran-Dube, Michelle ;

Shen, Hong ;

Nambu, Mitchell ;

Kung, Pei-Pei ;

Pairish, Mason ;

Jia, Lei ;

Meng, Jerry ;

Funk, Lee ;

Botrous, Iriny ;

McTigue, Michele ;

Grodsky, Neil ;

Ryan, Kevin ;

Padrique, Ellen ;

Alton, Gordon ;

Timofeevski, Sergei ;

Yamazaki, Shinji ;

Li, Quhua ;

Zou, Helen ;

Christensen, James ;

Mroczkowski, Barbara ;

Bender, Steve ;

Kania, Robert S. ;

Edwards, Martin P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6342-6363

[18] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[19] Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells [J].

Dong, Xuyuan ;

Fernandez-Salas, Ester ;

Li, Enxiao ;

Wang, Shaomeng .

NEOPLASIA, 2016, 18 (03) :162-171

[20] The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus [J].

Eichenmüller, B ;

Everley, P ;

Palange, J ;

Lepley, D ;

Suprenant, KA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (02) :1301-1309

← 1 2 3 4 5 6 7 8 9 10 →